21.55 USD
+0.03 (+0.14%)
21.65 USD
+0.1 (+0.46%)
ChartMill assigns a Buy % Consensus number of 70% to FUSN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 21.55. This target is -0.01% below the current price.
FUSN was analyzed by 18 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about FUSN.
In the previous month the buy percentage consensus was at a similar level.
FUSN was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-16 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-03-21 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-21 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-03-20 | JonesTrading | Downgrade | Buy -> Hold |
| 2024-03-20 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-03-20 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-03-20 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2024-03-20 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-03-19 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-03-19 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-03-19 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-03-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2024-03-19 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2024-03-19 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-03-19 | Jefferies | Downgrade | Buy -> Hold |
| 2024-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-01-26 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-01-05 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-05 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-12-27 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-12-27 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2023-12-20 | RBC Capital | Initiate | Outperform |
| 2023-10-03 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2023-09-29 | Oppenheimer | Initiate | Outperform |
| 2023-08-28 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-06-28 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-06-23 | Raymond James | Initiate | Outperform |
| 2023-03-30 | B. Riley Securities | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-01 | B. Riley Securities | Reiterate | Buy |
FUSION PHARMACEUTICALS INC / FUSN FAQ
What is the average price target for FUSION PHARMACEUTICALS INC (FUSN) stock?
18 analysts have analysed FUSN and the average price target is 21.55 USD. This implies a price decrease of -0.01% is expected in the next year compared to the current price of 21.55.
What is the consensus rating for FUSN stock?
The consensus rating for FUSION PHARMACEUTICALS INC (FUSN) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.